ClinicalTrials.gg
CompletedNCT01822613Updated Dec 19, 2020

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

A Phase 1 interventional study of LJM716 and BYL719 in Esophageal Squamous Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2016, 10 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 42 open to participants now, 50 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.

Enrollment
72nd of 120
48 · median 61
Started
2013
with 2 others
Phase 1
44 of 138
15 open now
Registered
56th of 138
by date
Lead sponsor
6 of 138
Novartis Pharmaceuticals

Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the 72nd largest by enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2013, is one of 44 in phase 1, and was the 56th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

42 of the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, or all of them as a file.
02

Study summary

To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.

Read the detailed description

The study design included a Phase 1b dose escalation portion to define the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) for the combination of LJM716 and alpelisib, followed by an open-label, randomized Phase 2 part to compare anti-tumor activity of LJM716-alpelisib combination versus physician's choice of second-line therapy (paclitaxel, docetaxel, irinotecan). However, the phase 2 part was not conducted as the study was terminated early due to limited anti-tumor activity with LJM716-alpelisib combination observed in phase 1b.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed esophageal squamous cell carcinoma (ESCC)
  • No more than one prior chemotherapy regimen for recurrent or ESCC (for Phase II only).
  • Progression during or after platinum-based therapy for recurrent or metastatic ESCC, or recurrence within 6 months of platinum-based chemotherapy or chemoradiotherapy for localized disease.

Exclusion criteria

Exclusion Criteria:

  • Patients who received prior phosphoinositide-3-kinase (PI3K) inhibitor or anti-receptor tyrosine-protein kinase erbB-3 (ERBB3 or HER3) antibody treatment, including bi-specific antibodies with HER3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (EGFR)-targeted agents are eligible)
  • Patients who do not have an archival or fresh tumor sample (or sections of it) available or readily obtainable.
  • Patients with central nervous system (CNS) involvement.
  • Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatment.
  • Patients who have received definitive radiotherapy ≤ 4 weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom ≥ 30% of the bone marrow was irradiated.
  • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    LJM716-BYL719 arm

    approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).

    Drug: LJM716 · Drug: BYL719

  • Active comparator
    Paclitaxel, Docetaxel or Irinotecan arm

    approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).

    Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan

Interventions

  • DrugLJM716

    LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.

  • DrugBYL719

    BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.

  • In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.

  • In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.

  • In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label

06

What researchers measure

Primary outcomes

  1. Phase Ib primary outcome measure: Incidence rate of dose limiting toxicities (DLTs).

    The open-label dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or Recommended Phase II Dose (s) guided by the safety (incidence of dose limiting toxicities), efficacy, pharmacokinetics and pharmacodynamics data.

    Time frame: approximately 8 months

  2. Phase II primary outcome measure: Progression free survival (PFS)

    Progression-free survival is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate assessment.

    Time frame: Every 6 weeks from the date of the baseline computed-tomography (CT) scan until the date of first documented evidence of disease progression or date of death, whichever comes first, assessed up to 24 months.

Secondary outcomes

  1. Safety and tolerability of the LJM716-BYL719

    This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.

    Time frame: Every 21 days from the date of the baseline visit until the end of study visit (about 5 months)

  2. Best overall response (BOR), per RECIST 1.1 (Ph 1b )

    BOR will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of baseline computed tomography (CT) scan until end of treatment visit (about 4 months)

  3. Plasma concentration versus time profiles Plasma PK parameters of LJM716, BYL719

    Plasma concentration versus time profiles Plasma PK parameters will be used to characterize the PK profiles of LJM716 and BYL719 when used in combination

    Time frame: Baseline, 2hr,4hr,8hr,24hr,48hr,96hr, 168 hr, every 21 days for 10 cycles (21 days each) and at end of treatment (about 4 months)

  4. Overall response rate (ORR) per RECIST 1.1 (Ph 1b )

    Overall response rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)

  5. Duration of response (DOR) per RECIST 1.1 (Ph 1b )

    Duration of response will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)

  6. Disease control rate (DCR) per RECIST 1.1 (Ph 1b )

    Disease control rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)

  7. Overall survival (OS) per RECIST 1.1 (for Ph 1b )

    Overall survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)

  8. Progression free survival (PFS) per RECIST 1.1 (Ph 1b )

    Progression free survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.

    Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of study visit (about 5 months)

07

Study locations

13 sites
  • University of Chicago Medical Center Dept of Onc
    Chicago, Illinois 60637, United States
  • Karmanos Cancer Institute Dept of Onc
    Detroit, Michigan 48201, United States
  • University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
    Houston, Texas 77030-4009, United States
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Singapore, 169610, Singapore
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Tainan, Taiwan ROC 70421, Taiwan
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Jun 2016, 34 months.

Of 42 phase 1 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 68. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2013
First posted
Apr 2, 2013
StartActual
Jul 26, 2013
Primary completionActual
Jun 3, 2016
CompletionActual
Jun 3, 2016
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01822613
Responsible party
Sponsor
First posted
Apr 2, 2013
Start date
Jul 26, 2013
Primary completion
Jun 3, 2016
Completion
Jun 3, 2016
Last update
Dec 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elgemtumab · Alpelisib

Start the discussion